{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:46:38Z","timestamp":1777131998615,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Tongren Hospital Internal Fund","award":["ynkyxlj\u8bb8\u5f8b\u63771"],"award-info":[{"award-number":["ynkyxlj\u8bb8\u5f8b\u63771"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82575256"],"award-info":[{"award-number":["82575256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2024A1515030161, 2023A1515012148"],"award-info":[{"award-number":["2024A1515030161, 2023A1515012148"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Special Foundation of Guangdong Educational Committee","award":["2024ZDZX2028"],"award-info":[{"award-number":["2024ZDZX2028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29593-z","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:39:09Z","timestamp":1764250749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance analysis of vision disorders relating to brimonidine treatment and mechanism study using network toxicology and molecular docking"],"prefix":"10.1038","volume":"15","author":[{"given":"Lvjie","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiansong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuipu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"29593_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.podrm.2022.11.001","volume":"48","author":"AH Bakheit","year":"2023","unstructured":"Bakheit, A. H., Alomar, A. M., Darwish, H., Alkahtani, H. M. & Brimonidine Profiles Drug Subst. Excip Relat. Methodol. 48, 1\u201337 (2023).","journal-title":"Profiles Drug Subst. Excip Relat. Methodol."},{"key":"29593_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/14656566.2018.1544241","volume":"20","author":"DJ Oh","year":"2019","unstructured":"Oh, D. J., Chen, J. L., Vajaranant, T. S. & Dikopf, M. S. Brimonidine tartrate for the treatment of glaucoma. Expert Opin. Pharmacother. 20, 115\u2013122 (2019).","journal-title":"Expert Opin. Pharmacother"},{"key":"29593_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/02713683.2020.1800046","volume":"46","author":"G Suzuki","year":"2021","unstructured":"Suzuki, G. et al. Ocular and systemic pharmacokinetics of brimonidine and Brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations. Curr. Eye Res. 46, 380\u2013386 (2021).","journal-title":"Curr. Eye Res."},{"key":"29593_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/17425250802457609","volume":"7","author":"SJ Fudemberg","year":"2008","unstructured":"Fudemberg, S. J., Batiste, C. & Katz, L. J. Efficacy, safety, and current applications of brimonidine. Expert Opin. Drug Saf. 7, 795\u2013799 (2008).","journal-title":"Expert Opin. Drug Saf."},{"key":"29593_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1055\/s-0035-1563580","volume":"35","author":"RA Egan","year":"2015","unstructured":"Egan, R. A. & LaFrance, W. C. Jr. Functional vision disorder. Semin Neurol. 35, 557\u2013563 (2015).","journal-title":"Semin Neurol."},{"key":"29593_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/IJG.0b013e3182953aef","volume":"24","author":"AA Shah","year":"2015","unstructured":"Shah, A. A., Modi, Y., Thomas, B., Wellik, S. R. & Galor, A. Brimonidine allergy presenting as vernal-like keratoconjunctivitis. J. Glaucoma. 24, 89\u201391 (2015).","journal-title":"J. Glaucoma"},{"key":"29593_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu, R. J., Krantz, M. S., Phillips, E. J. & Stone, C. A. Jr. Emerging causes of Drug-Induced anaphylaxis: A review of Anaphylaxis-Associated reports in the FDA adverse event reporting system (FAERS). J. Allergy Clin. Immunol. Pract. 9, 819\u2013829e812 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"29593_CR8","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. EClinicalMedicine 59, 101967 (2023).","journal-title":"EClinicalMedicine"},{"key":"29593_CR9","doi-asserted-by":"publisher","first-page":"111767","DOI":"10.1016\/j.fct.2020.111767","volume":"145","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective. Food Chem. Toxicol. 145, 111767 (2020).","journal-title":"Food Chem. Toxicol."},{"key":"29593_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000531132","volume":"148","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Hydroxychloroquine attenuates hERG channel by promoting the membrane channel degradation: computational simulation and experimental evidence for QT-Interval prolongation with hydroxychloroquine treatment. Cardiology 148, 310\u2013323 (2023).","journal-title":"Cardiology"},{"key":"29593_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting False-Positive associations. Drug Saf. 43, 479\u2013487 (2020).","journal-title":"Drug Saf."},{"key":"29593_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13, 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"29593_CR13","doi-asserted-by":"publisher","first-page":"8105","DOI":"10.1021\/acs.jcim.4c01445","volume":"64","author":"C Yan","year":"2024","unstructured":"Yan, C. et al. 3DSTarPred: A web server for target prediction of bioactive small molecules based on 3D shape similarity. J. Chem. Inf. Model. 64, 8105\u20138112 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"29593_CR14","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"29593_CR15","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013d646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"29593_CR16","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216\u2013w221 (2022).","journal-title":"Nucleic Acids Res."},{"key":"29593_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11030-017-9772-5","volume":"21","author":"C Cai","year":"2017","unstructured":"Cai, C. et al. In Silico prediction of ROCK II inhibitors by different classification approaches. Mol. Divers. 21, 791\u2013807 (2017).","journal-title":"Mol. Divers."},{"key":"29593_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/pro.3934","volume":"30","author":"DS Goodsell","year":"2021","unstructured":"Goodsell, D. S., Sanner, M. F., Olson, A. J. & Forli, S. The AutoDock suite at 30. Protein Sci. 30, 31\u201343 (2021).","journal-title":"Protein Sci."},{"key":"29593_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","volume":"24","author":"D Seeliger","year":"2010","unstructured":"Seeliger, D. & de Groot, B. L. Ligand Docking and binding site analysis with PyMOL and Autodock\/Vina. J. Comput. Aided Mol. Des. 24, 417\u2013422 (2010).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"29593_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"29593_CR21","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram, H., Kolko, M., Friedman, D. S. & Gazzard, G. Glaucoma: now and beyond. Lancet 402, 1788\u20131801 (2023).","journal-title":"Lancet"},{"key":"29593_CR22","doi-asserted-by":"publisher","first-page":"m569","DOI":"10.1136\/bmj.m569","volume":"368","author":"S Zhou","year":"2020","unstructured":"Zhou, S., Carroll, E., Nicholson, S. & Vize, C. J. Blurred vision. Bmj 368, m569 (2020).","journal-title":"Bmj"},{"key":"29593_CR23","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators, & Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators, & Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study. Lancet Glob Health. 9, e144\u2013e160 (2021).","journal-title":"Lancet Glob Health"},{"key":"29593_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/B978-0-444-53486-6.00045-4","volume":"136","author":"C Ellenberger","year":"2016","unstructured":"Ellenberger, C. Visual impairment. Handb. Clin. Neurol. 136, 887\u2013903 (2016).","journal-title":"Handb. Clin. Neurol."},{"key":"29593_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605\u2013635 (2017).","journal-title":"Cell"},{"key":"29593_CR26","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","volume":"21","author":"VER Parker","year":"2019","unstructured":"Parker, V. E. R. et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet. Med. 21, 1189\u20131198 (2019).","journal-title":"Genet. Med."},{"key":"29593_CR27","doi-asserted-by":"publisher","first-page":"e0295813","DOI":"10.1371\/journal.pone.0295813","volume":"19","author":"R Guan","year":"2024","unstructured":"Guan, R., Kang, Z., Li, L., Yan, X. & Gao, T. PIK3CA regulates development of diabetes retinopathy through the PI3K\/Akt\/mTOR pathway. PLoS One. 19, e0295813 (2024).","journal-title":"PLoS One"},{"key":"29593_CR28","first-page":"1365","volume":"43","author":"X Ma","year":"2020","unstructured":"Ma, X., Jin, L., Lei, X., Tong, J. & Wang, R. MicroRNA\u2013363\u20133p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt\/mTOR signaling pathway by targeting PIK3CA. Oncol. Rep. 43, 1365\u20131374 (2020).","journal-title":"Oncol. Rep."},{"key":"29593_CR29","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/jcp.27044","volume":"234","author":"T Tsukamoto","year":"2019","unstructured":"Tsukamoto, T., Kajiwara, K., Nada, S. & Okada, M. Src mediates TGF-\u03b2-induced intraocular pressure elevation in glaucoma. J. Cell. Physiol. 234, 1730\u20131744 (2019).","journal-title":"J. Cell. Physiol."},{"key":"29593_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00125-020-05299-x","volume":"64","author":"H Xie","year":"2021","unstructured":"Xie, H. et al. Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src\/Akt\/cofilin signalling in experimental diabetic retinopathy. Diabetologia 64, 211\u2013225 (2021).","journal-title":"Diabetologia"},{"key":"29593_CR31","first-page":"547","volume":"35","author":"YX Qi","year":"2021","unstructured":"Qi, Y. X., Su, X. J., Wei, L. L. & Zhang, J. Erythropoietin inhibits apoptosis of retinal ganglion cells induced by high glucose through JNK signaling pathway. J. Biol. Regul. Homeost. Agents. 35, 547\u2013557 (2021).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"29593_CR32","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","volume":"59","author":"J Garcia Fortanet","year":"2016","unstructured":"Garcia Fortanet, J. et al. Allosteric Inhibition of SHP2: identification of a Potent, Selective, and orally efficacious phosphatase inhibitor. J. Med. Chem. 59, 7773\u20137782 (2016).","journal-title":"J. Med. Chem."},{"key":"29593_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s10753-021-01555-3","volume":"45","author":"M Zhu","year":"2022","unstructured":"Zhu, M. et al. Crosstalk between RPE cells and choroidal endothelial cells via the ANXA1\/FPR2\/SHP2\/NLRP3 Inflammasome\/Pyroptosis axis promotes choroidal neovascularization. Inflammation 45, 414\u2013427 (2022).","journal-title":"Inflammation"},{"key":"29593_CR34","doi-asserted-by":"publisher","first-page":"e22841","DOI":"10.1002\/jbt.22841","volume":"35","author":"L Xu","year":"2021","unstructured":"Xu, L., Li, Z., Rong, J. & Lang, L. Effect of regulation of the NRG1\/ErbB4 signaling pathway on the visual cortex synaptic plasticity of amblyopic adult rats. J. Biochem. Mol. Toxicol. 35, e22841 (2021).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"29593_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2006.09.001","volume":"45","author":"N Kanazawa","year":"2007","unstructured":"Kanazawa, N. Dendritic cell immunoreceptors: C-type lectin receptors for pattern-recognition and signaling on antigen-presenting cells. J. Dermatol. Sci. 45, 77\u201386 (2007).","journal-title":"J. Dermatol. Sci."},{"key":"29593_CR36","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.4049\/jimmunol.1502355","volume":"196","author":"EJ Lee","year":"2016","unstructured":"Lee, E. J. et al. Mincle activation and the Syk\/Card9 signaling axis are central to the development of autoimmune disease of the eye. J. Immunol. 196, 3148\u20133158 (2016).","journal-title":"J. Immunol."},{"key":"29593_CR37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/cei.13021","volume":"190","author":"BR Brown","year":"2017","unstructured":"Brown, B. R. et al. Fungal-derived cues promote ocular autoimmunity through a Dectin-2\/Card9-mediated mechanism. Clin. Exp. Immunol. 190, 293\u2013303 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"29593_CR38","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3892\/mmr.2014.2859","volume":"11","author":"D Gui","year":"2015","unstructured":"Gui, D. et al. HIF\u20131 signaling pathway involving iNOS, COX\u20132 and caspase\u20139 mediates the neuroprotection provided by erythropoietin in the retina of chronic ocular hypertension rats. Mol. Med. Rep. 11, 1490\u20131496 (2015).","journal-title":"Mol. Med. Rep."},{"key":"29593_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12964-023-01138-9","volume":"21","author":"W Xu","year":"2023","unstructured":"Xu, W. et al. Inhibiting HIF-1 signaling alleviates HTRA1-induced RPE senescence in retinal degeneration. Cell. Commun. Signal. 21, 134 (2023).","journal-title":"Cell. Commun. Signal."},{"key":"29593_CR40","doi-asserted-by":"publisher","first-page":"1271118","DOI":"10.3389\/fimmu.2023.1271118","volume":"14","author":"JJ Anders","year":"2023","unstructured":"Anders, J. J., Elwood, B. W., Kardon, R. H. & Gramlich, O. W. Acriflavine, a HIF-1 inhibitor, preserves vision in an experimental autoimmune encephalomyelitis model of optic neuritis. Front. Immunol. 14, 1271118 (2023).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29593-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:13:04Z","timestamp":1777129984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29593-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29593"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29593-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45522"}}